Social anxiety is a common disorder that has negative impacts across multiple domains of function. Several clinical groups are at elevated risk for social anxiety, including those with fragile X syndrome and those with autism spectrum disorder. Measuring social anxiety in these clinical subgroups is fraught with challenge, however, given the complexity of social anxiety and measurement limitations that are particularly acute in persons with neurodevelopmental disorders.
Social anxiety is a common disorder that has negative impacts across multiple domains of function. Several clinical groups are at elevated risk for social anxiety, including those with fragile X syndrome and those with autism spectrum disorder. Measuring social anxiety in these clinical subgroups is fraught with challenge, however, given the complexity of social anxiety and measurement limitations that are particularly acute in persons with neurodevelopmental disorders.
The over-arching aim of this study was to contribute to our understanding of the nature of social anxiety in fragile X syndrome and its association with autism spectrum disorder. To address this aim, we created a multi-faceted composite representing behavioral and biological aspects of social anxiety and examined differences in two adolescent and young adult-aged groups: 59 males with fragile X syndrome and 18 males with autism spectrum disorder. Results indicated a lower score on the multivariate composite for the males with fragile X syndrome relative to autism spectrum disorder but with evidence that traits of autism and social anxiety overlap. We conclude that measuring anxiety and autism traits in fragile X syndrome and autism spectrum disorder is complex with features that overlap and interact in a dynamic manner.
| INTRODUCTION
Anxiety is a multi-faceted construct associated with cognitive, affective, and biological factors that interact dynamically over the life course. Anxiety disorders constitute a common and debilitating mental health problem in adolescents and young adults, with 30% meeting criteria for an anxiety disorder and many more displaying symptoms of anxiety but not meeting full diagnostic criteria (Kessler & Wang, 2008) . Given the high prevalence and significant negative impact of anxiety, research has increasingly focused on understanding the extent, nature, and sources of anxiety in clinical subgroups that are at elevated risk. Individuals with intellectual disability (ID) represent a clinical subgroup that presents with the full range of mental illnesses and are four times more likely to have anxiety than typical controls (Green, Berkovits, & Baker, 2014) . Comorbidity of anxiety in persons with ID reduces function across multiple domains and inhibits their already impaired learning (Schneier et al., 1994) , thereby highlighting the importance of identification, prevention, and treatment of anxiety in these individuals.
Characterizing anxiety in persons with ID is fraught with challenges, however, given both measurement limitations and ambiguous diagnostic demarcation. Measurement limitations reflect the lack of available standardized measures normed for persons with ID in addition to the inapplicability of many available measures, which typically rely on self-report, to ID populations given blunted self-reflection and communication impairments. Informant reports, although useful, are subject to many of the same limitations as in intellectually typical populations (e.g., limited knowledge of the informant about the full range of contexts in which the target individual participates). Likewise, differential diagnosis of anxiety co-morbid with ID is complicated given overlapping features between the disorders and minimal established guidelines upon which to make distinctions. Also, there has been an over-reliance in research on ID populations on conceptualizing and measuring anxiety as a unitary disorder, rather than recognizing discrete anxiety disorders. As a result, little is known about the nature and expression of anxiety in persons with ID, which makes the development of treatments and prevention strategies for this population difficult.
Social anxiety disorder, also known as social phobia, is a distinct anxiety disorder that is characterized by discomfort and/or fear around social interaction (American Psychological Association, 2013) .
Social anxiety is one of the most prevalent and impairing anxiety disorders, with nearly 10% of the general population (Nagata, Suzuki, & Teo, 2015) and a large subgroup of individuals with ID meeting criteria for the disorder. Diagnosing social anxiety in persons with ID is challenging, however, because social impairments are often associated with low cognitive skills and the differential diagnosis of social anxiety co-morbid with ID requires determining that the clinical presentation is not best accounted for by ID alone, which can be very difficult in practice. Moreover, like anxiety more generally, social anxiety is multidimensional and may be manifested in at least partly different ways across individuals with ID or in combination with other disorders.
In this study, we aimed to capture the features of social anxiety using a composite measure comprised of behavioral features derived from multiple sources (parent ratings and direct observation) and a biomarker (cortisol) across two distinct groups with ID, each of whom is at elevated risk for social anxiety disorder. Our goal was to determine if social anxiety is manifested to different degrees, as different symptom profiles, or with different correlates between fragile X syndrome (FXS) and nonsyndromic autism spectrum disorder (ASD). We use the term nonsyndromic to recognize ASD in individuals without a known genetic syndrome (e.g., FXS, tuberous sclerosis). Given that social anxiety is thought to characterize both of these neurodevelopmental disorders, studies that contrast features of social anxiety across these disorders have the potential to contribute to increased phenotypic specificity. Moreover, these data will advance our understanding of how common behavioral traits may reflect unique underlying problems across disorders and may provide clues to possible differential treatment options across the two disorders.
| Anxiety in nonsyndromic ASD
A high prevalence of anxiety disorders has been reported in individuals with nonsyndromic ASD, with 40%-60% of youth meeting diagnostic criteria for an anxiety disorder and up to 37% diagnosed with social anxiety disorder (Kerns et al., 2014; White, Oswald, Ollendick, & Scahill, 2009) . Although nearly 40% of persons with nonsyndromic ASD have ID (Christensen et al., 2016) , most studies of social anxiety in nonsyndromic ASD have examined the relationship of social anxiety to IQ among individuals in the typical IQ range, with little work focused on individuals with comorbid ID and ASD. This is of concern given that cognitive level has clearly been reported as an important factor in the prevalence and profile of anxiety disorders in other populations (Reardon, Gray, & Melvin, 2014) . Specifically, generalized anxiety disorder and separation anxiety were reported as more prevalent in youth with nonsyndromic ASD not having an ID (IQ > 70) than in those with nonsyndromic ASD and a comorbid ID, whereas the prevalence of specific phobia, panic disorder, and social phobia were not different in those with and without comorbid ID (Sukhodolsky et al., 2008) . The finding of an effect of IQ on the prevalence of anxiety disorders in nonsyndromic ASD has also been found in studies of samples of ASD without ID (Kerns et al., 2014) . To date, only one study has examined social anxiety in persons with comorbid ASD and ID contrasted to an etiologically distinct group with ID (Thurman, McDuffie, Hagerman, & Abbeduto, 2014) . This work is critical to determine if the diagnosis or treatment of social anxiety in "low functioning" children with ASD who have comorbid ID should be unique or similar to that in those not having ID.
A number of mechanisms have been proposed to account for elevated social anxiety in ASD. In a large-scale twin study, results indicated that children with ASD, their siblings diagnosed with the broader autism phenotype, and their siblings unaffected by ASD all displayed heightened social anxiety compared to typical controls implying a strong heritable component (Hallett et al., 2013) . Neural indicators reflecting increased lateral prefrontal activation during anticipation to reward (Mikita et al., 2016) and increased bilateral amygdala activation to social reward that parallels that of persons with social anxiety disorder have been reported in individuals with ASD (Richey et al., 2014) . Finally, children with ASD and a co-morbid anxiety disorder displayed blunted cortisol and heart rate responses to stress that distinguished them from children with ASD who did not have anxiety and from a typically developing control group, suggesting that nonadaptive physiological modulation may be implied mechanistically (Hollocks, Howlin, Papadopoulos, Khondoker, & Simonoff, 2014) .
Although it is clear that social anxiety is highly prevalent in persons with ASD, there is a lack of consensus as to whether social anxiety in ASD is a common consequence of ASD (i.e., is part of the phenotype) or whether social anxiety is a unique comorbidity distinct from ASD (Kerns et al., 2014) . Furthermore, controversy exists regarding whether the phenomenology of social anxiety in ASD is qualitatively similar to traditional Diagnostic and Statistical Manual (DSM) categorization or distinct and more reflective of ASD features (Kerns et al., 2014) . In fact, a proposal has been made to designate anxiety disorders in ASD as either "traditional," aligning with standard DSM criteria, or "atypical," representing inconsistencies with DSM conventions and calling for the development of new instruments or the modifications of existing instruments to accurately reflect these categorizations of anxiety (Kerns et al., 2014) .
In summary, social anxiety is highly prevalent in ASD. Cognitive ability likely has an effect on the prevalence and profile of social anxiety disorders in persons with ASD; however, the nature of this relationship is not consistent or clear. In fact, majority of studies examining social anxiety in ASD has excluded persons with ID, have focused on the occurrence of symptoms of social anxiety rather than social anxiety disorder, and have seldom included cross-syndrome comparisons. The resulting gaps in our understanding of social anxiety in ASD will be addressed in the present study.
| Anxiety in FXS
FXS is a single-gene disorder that affects 1 in 3700 males and is the leading known inherited cause of ID (Schneider, Hagerman, & Hessl, 2009 ). Approximately 86% of males with FXS meet diagnostic criteria for an anxiety disorder (Cordeiro, Ballinger, Hagerman, & Hessl, 2011) reduced employment, and higher financial burden at a family level (Ouyang, Grosse, Raspa, & Bailey, 2010) . Although anxiety is frequently reported among males with FXS, only a single study has employed a diagnostic measure to evaluate anxiety, with most studies relying instead on broad-based rating scales of severity of anxietyrelated symptoms. The majority of symptom-based research has reported elevations across broad indicators of anxiety and across multiple anxiety disorders, with social anxiety reported as particularly problematic (Roberts, Weisenfeld, Hatton, Heath, & Kaufmann, 2007; Thurman et al., 2014; Wheeler et al., 2014) . These symptom-based findings are supported by diagnostic data indicating that social phobia was one of the most common anxiety disorders in males with FXS and ID, with 35% meeting DSM-IV criteria (Cordeiro et al., 2011) . Of note, when the requirement of "worry" was removed in acknowledgment that many of the individuals could not express worry due to their ID, the prevalence of social phobia rose to 60% (Cordeiro et al., 2011) .
Compared to published work on idiopathic ID (n = 474; Dekker & Koot, 2003) , males with FXS display rates of social phobia that are nearly 35 times higher than in idiopathic ID (60% vs. 2%, respectively).
The prevalence of social anxiety is significantly more common in adults than in children (Cordeiro et al., 2011) , highlighting the importance of examining the predictors and consequences of social anxiety during the late adolescent and early adult years. This effort would help to direct treatment efforts aimed at improving adult outcomes in FXS, which are substantially lower than expected for their chronological age and IQ (Hartley et al., 2011 ).
Importantly, not only do males with FXS demonstrate elevated rates of social anxiety, but they also demonstrate increased risk for ASD (e.g., Clifford et al., 2007; Harris et al., 2008) . Because the behavioral indicators of ASD overlap with those of social anxiety (e.g., gaze avoidance), it can be difficult to determine whether co-occurring symptoms contribute to diagnostic error with persons diagnosed with ASD rather than anxiety or if they represent a "true" comorbidity. In the only study to employ diagnostic measures of anxiety in FXS, the prevalence of social anxiety in males with FXS who met criteria for ASD was higher than those with FXS without ASD (Cordeiro et al., 2011) . Likewise, in a series of studies examining dynamic aspects of social avoidance as one dimension of social anxiety (Roberts et al., 2007; Roberts et al., 2009) , initial gaze avoidance during an interaction with an unfamiliar person appeared universal across boys with FXS with and without elevated symptoms of ASD, whereas sustained gaze avoidance was unique only to those with increased severity of ASD symptoms. Thus, initial within-group evidence suggests that DSMbased diagnostic categorization of social anxiety and observations of social withdrawal may differentiate males with FXS who do and do not have co-morbid ASD. However, it is again unclear if the social anxiety is comorbid with ASD or "biases" the clinical diagnosis toward ASD. In contrast, in one of the few cross-syndrome studies published, social anxiety did not differ across FXS (with or without ASD) and nonsyndromic ASD groups (Thurman et al., 2014) . That said, the authors noted that social anxiety scores were correlated with general anxiety scores in FXS, but not in nonsyndromic ASD, suggesting between group differences in either the factors or mechanisms underlying performance on this measure (Thurman et al., 2014) . Thus, this is a complex issue and it appears that findings depend greatly on measurement of social avoidance, suggesting the need to integrate multiple measurements of avoidance in assessing anxiety in FXS and ASD. Barlow's diathesis-stress model (Barlow, 2002) . Hyperarousal in FXS is a well-established phenomenon with consistent reports of elevated baseline heart activity (Hall, Lightbody, Huffman, Lazzeroni, & Reiss, 2009; Klusek, Roberts, & Losh, 2015 , for a review; Roberts, Tonnsen, Robinson, & Shinkareva, 2012) and heightened salivary cortisol (Hardiman & Bratt, 2016 , for a review; Hessl et al., 2002) .
Evidence supporting physiological arousal in direct association with anxiety symptoms, however, is mixed, with most work indicating systemic hyperarousal across baseline and stress-inducing conditions in FXS (Hall et al., 2009; Klusek, Martin, & Losh, 2013; Tonnsen, Malone, Hatton, & Roberts, 2013) . Specific stress conditions, including conversation, the approach of a stranger, and cognitive challenges have not been associated with stimulus-bound increases in autonomic arousal as measured by heart activity (Roberts, Boccia, Bailey, Hatton, & Skinner, 2001; Klusek et al., 2013; Tonnsen et al., 2013) . Likewise, a number of behaviors reflective of elevated stress, including crying and task avoidance have not been associated with elevated cortisol (see Hardiman & Bratt, 2016 for review). However, elevated salivary cortisol has been linked to features of social anxiety, as indexed by gaze avoidance (Hall et al., 2009 ), physical avoidance (Roberts et al., 2009) , and elevated parent ratings of social avoidance (Matherly et al., in press ). Thus, physiological arousal may contribute to the presence and expression of social anxiety in FXS, but the bulk of evidence supports the hypothesis that it is more likely a systemic rather than a stimulus-bound reaction (e.g., a pervasive condition of hyperarousal versus elevated arousal in response to discrete conditions).
In sum, existing evidence indicates that anxiety is common in males with FXS, with social anxiety being particularly prevalent and impairing. However, the associations of social anxiety with ID severity, ASD symptom severity, and chronological age are not well established in FXS, and differences in social anxiety presentation and source relative to nonsyndromic ASD are also unclear. These gaps in the literature can be attributed to the sparsity of studies, wide distribution of chronological ages in most work, a focus on social anxiety disorder versus symptoms of social anxiety, and measurement challenges. The present study was designed to address these gaps and limitations.
| CURRENT STUDY
Social anxiety is clearly prevalent and impairing in both FXS and nonsyndromic ASD, two etiologically distinct disorders that have a number of overlapping phenotypic features. Diagnostic determination of social anxiety in these neurodevelopmental disorders is made challenging by the multidimensional nature of social anxiety, features that overlap across disorders, and limitations in measurement that acutely impact studies of social anxiety in persons with ID. However, accumulating evidence indicates that it is critical to diagnose social anxiety in persons with ID so as to provide a foundation for the development of maximally efficacious treatments. As noted, such work is complex, and the inclusion of multiple measures of social anxiety, integration of biomarkers, and the use of cross-syndrome comparisons are essential to maximize the impact of this research (White et al., 2009 ).
The overarching goal of this study is to advance our understanding of the nature of social anxiety in males with FXS and its unique and shared associations with ASD. We accomplish this by creating a putative multivariate composite of social anxiety representing both behavioral and biological dimensions and examining mean differences on this composite across two groups-FXS and nonsyndromic ASD.
We then conduct follow up analyses to determine which scales drive the group differences and how the groups differ on those scales. The objective is to understand similarities and differences in the extent, manifestation, and correlates of social anxiety between FXS and nonsyndromic ASD. Guanine Guanine (CGG) repeats) was confirmed for the participants in the FXS group and ruled out in the nonsyndromic ASD group through review of records documenting molecular genetic testing prior to study participation. Of the FXS group, 62.7% were prescribed medication(s) at the time of the study, with 47.5% of the FXS group on medication(s) for anxiety. In the nonsyndromic ASD group, 55.6% were prescribed medication(s) with 27.8% on medication(s) for anxiety. In the FXS group, use of anxiety medication was significantly correlated with Autism Diagnostic Observation Schedule-Second Edition (ADOS-2) severity score (r = .35, p < .01), but not with any of the social anxiety symptom variables. There were no significant correlations between anxiety medication use and any symptom variables in the nonsyndromic ASD group. Earlier social avoidance studies from our group (Roberts et al., 2007; Roberts et al., 2009 ) employed an experimental measure that included responses to both initial and prolonged social interaction across three dimensions of behavior: eye contact, facial expression, and bodily movement. Our results indicated that the majority of male children with FXS and less severe autism symptoms displayed initial social avoidance with a "warm-up" evident over time (Roberts et al., 2009 ).
These data suggested that the initial social response of the children with FXS likely reflected social anxiety related to the onset of the research assessment.
In the present study, SAS ratings were made on three dimensions of behavior (physical movement, facial expression, and eye contact) upon initial interaction (i.e., the first minute of interaction when the participant arrives at the research site and first encounters the examiners) and after sustained interaction (i.e., the last hour of interaction to reflect social avoidance after given time to "warm up"). Physical approach represents bodily movement, with a high score indicating active avoidance such as walking away from the examiner. A high score on facial expression reflects elevated shyness or fear reflected by the position of the mouth, eyes, and brow regions. A high score on eye contact indicates minimal or poorly modulated eye contact. Data for this study came from the first minute of interaction on the first day of a 2-day assessment averaged across all three dimensions as our focus was on basal levels of anxiety rather than in response to an experimental press. Raters were trained to ≥80% reliability on the SAS prior to data collection with an inter-rater reliability rate of 87% for the initial ratings for the first assessment day. Cronbach's alpha for the mean initial interaction SAS score across the three dimensions for this study was α = .76. Raw scores for the measure range from 0 to 5were used for analysis. Ratings were made in real-time from direct observation.
| Baseline cortisol
Baseline cortisol reflects activation of the hypothalamic-pituitaryadrenal axis, which contributes to emotional and behavioral regulation through its role as a biological stress response system. Elevated chronic or stimulus-bound responses represent a maladaptive response to stress and are associated with physical and mental health consequences including anxiety disorders (Zorn et al., 2017) . Salivary cortisol was collected using either a salivette that was placed in the participant's mouth for 1 min (64% of sample) or using passive drool methods, depending on participant compliance. Saliva was collected via both methods on a subset of participants (n = 28) to test comparability across collection methods; the values obtained across methods were highly correlated at r = .73, p = .01. Samples were taken within 15 min of arrival at the testing site on the first day of the 2-day assessment and prior to initiation of the research assessment as a "pre-assessment baseline" at approximately the same time of day (9:00 a.m.). To reduce potential contamination effects, participants were asked to refrain from drinking or eating dairy products or those with citric acid for approximately an hour prior to arrival (Schwartz, Granger, Susman, Gunnar, & Laird, 1998) . The samples were then stored in a −20 C freezer until shipped and analyzed by the Daacro Saliva Lab at Trier University, Trier, Germany. Cortisol levels were measured in micrograms/deciliters and determined employing a competitive solid phase time-resolved fluorescence immunoassay with flouromeric end point detection (DELFIA) using radioimmunoassay (Hessl et al., 2002; Roberts et al., 2009 ). The intra-assay coefficient of variation was between 4.0% and 6.7%, and the corresponding interassay coefficients of variation were between 7.1% and 9.0%. Each sample was assayed in duplicate with duplicate correlations of >.95.
| Anxiety depression and mood scale: Avoidance subscale
The Comparison Score is measured from 1 to 10 in the ADOS-2 and were used for analysis in the current study. The ADI-R is a standardized, diagnostic parent interview that assesses the presence of ASD behaviors relating to language and communication, reciprocal social interactions, and restricted, repetitive, or stereotyped behaviors. The ADI-R results in a categorical diagnosis of autism or no autism. In this study, the biological mother was interviewed in the ADI-R. Both the ADI-R and ADOS-2 were administered and scored by graduate-level professionals who had completed research reliability training. A second scorer measured inter-rater reliability in a randomly selected 15% of administrations. Across both sites, the inter-rater agreement was 81%
for the ADOS-2 total score and 91% for the ADI-R total score. Using the Risi criteria (Risi et al., 2006) we subdivided the group with FXS into those with ASD (n = 44) and those without ASD (n = 15) to supplement our analyses using the ADOS-2 as a continuous measure.
This was done to contribute to the ongoing debate regarding the nature of ASD in those with FXS. Thus, the primary analyses used the ADOS-2 calibrated severity score as a continuous measure with supplemental analyses examining ASD as a categorical factor.
| The Leiter international performance scale-revised
The were used in the analysis of group differences rather than standard scores.
| Procedures
Although the assessment was conducted over 2 consecutive days, the 
| Data analysis
Analyses were conducted in SPSS (IBM Corp., 2015) . First, descriptive statistics were examined for each of the anxiety symptom scales (Tables 1 and 2 ) to examine means and ranges across groups and to identify potential violations of distributional assumptions. For our primary research question, group differences on a multivariate outcome variable (comprised of the SAS score, the ADAMS Social Anxiety scale score, baseline salivary cortisol, and the CBCL Anxiety Problems scale score) were tested with a one-way, between-subjects multivariate analysis of covariance (MANCOVA). This analytical approach was implemented given our focus on manifest variable comparisons consistent with the capacity of the data, which did not support the use of factor analysis (March, Hau, Balla, & Grayson, 1998) . In addition, our sample size was inadequate for latent variable models (e.g., factor analyses, structural equation modeling), and we opted to use the MAN-COVA as the most robust analytic model that allows for correlated dependent variables by design. Levene's test indicated that the assumption of homogeneity of variance for the analysis was not violated (p = .409). Follow-up analyses corrected with Tukey's Honestly Significant Difference (HSD) for multiple comparisons assessed specific group differences on the multivariate anxiety outcome. Finally, linear discriminant function coefficients were examined to determine how each of the dependent variables of the multivariate outcome contributed to differentiation between groups. These coefficients were subsequently multiplied by standardized z-scores for each outcome variable to create a weighted linear composite (Enders, 2003) for assessing the relationship between the multivariate anxiety outcome and ASD severity. To facilitate interpretation, the inverse was taken for the multivariate composite score so that a higher score reflected increased anxiety symptoms. To follow up on these primary findings, we tested whether mean differences were present across groups on those measures found to most strongly contribute to the multivariate composite using an ANOVA. We examined group differences first keeping the FXS group intact and comparing them to the nonsyndromic ASD group. We followed up these analyses by creating three groups, with the nonsyndromic ASD group contrasted to the group with FXS determined to meet diagnostic criteria for ASD (Risi , 2006) and the group with FXS not meeting criteria for ASD.
These complementary approaches were used to contribute to the debate in the field regarding viewing ASD severity as a continuous symptom-based variable or as a categorical variable. ASD symptom severity and Leiter-R growth scores were included as covariates in the two-group continuous models with only Leiter-R growth scores covaried in the three-group analyses given that ASD symptom severity is accounted for by the categorical designation and covariation of ASD symptom severity in the three-group analyses would violate assumptions given that a true preexisting group difference that is dependent on the group membership exists (Miller & Chapman, 2001 ). 
| Categorical analyses
In this 3-group (FXS without ASD, FXS with ASD, and nonsyndromic ASD) analysis with the three anxiety symptom scales with IQ co-varied, the MANCOVA did not reach significance λ = .96, F(2, 67) = .8379, p = .478, R 2 c = .038.
| Follow-up analyses 4.2.1 | Continuous analysis
To follow-up on the primary analyses, we conducted two ANOVAs covarying for IQ and ADOS-2 symptom severity to examine group differences (FXS vs. nonsyndromic ASD) on the measures that most strongly contributed to group discriminations on the composite. Although the FXS group had a higher mean score than the nonsyndromic ASD group on the SAS (2.288 vs. 2.148, respectively), the groups were not significantly different; F(1, 74) = .149, p = .701, R 2 c = .142). Likewise, the nonsyndromic ASD group had a higher mean score than the FXS group on the ADAMS (8.33 vs. 6.85, respectively), but the group difference was not significant; F(1, 74) = .193, p = .661, R 2 c = .085). To enhance interpretation of the multivariate composite with respect to its relationship to ASD severity, a Pearson correlation between the ADOS-2 and composite variable was computed. Results indicated a moderate relationship in both groups: r = .38, p = .007 in FXS and r = .49 and p = .037 in nonsyndromic ASD. Figure 1 illustrates a scatterplot of this relationship. Note. Coefficients are regression weights that are multiplied by the z-scores used to create the multivariate anxiety composite with a higher coefficient reflecting higher symptomatology. Initial composite analyses utilizing all four anxiety measures indicated that no significant latent factors emerged and that cortisol contributed least to the composite. To refine the model, we excluded cortisol from the composite. New analyses with the three anxiety indices (cortisol dropped) suggested a single, multidimensional construct that was significant. We confirmed this by computing correlations that indicated no relationship between cortisol and the other three anxiety indices or the anxiety composite. These findings suggest that baseline cortisol represents a variable independent from the other three anxiety markers. This is consistent with our previous work indicating no relationship of baseline cortisol to initial SAS ratings in boys with FXS (Roberts et al., 2009) . It is also consistent with evidence from an independent group of investigators showing that cortisol was not related to the anxiety subscale of the CBCL in males with FXS (Hessl et al., 2002) .
| Categorical analysis
In studies examining the relationship of ASD symptoms to cortisol in FXS, elevated baseline cortisol has been associated with increased ASD symptom severity (Roberts et al., 2009 ) and reduced eye contact (Hall et al., 2009 ) with a tendency to associate positively with the withdrawal subscale of the CBCL (Hessl et al., 2001) . In contrast, elevated baseline cortisol has been associated with reduced ASD symptom severity in one study (Hall et al., 2009 ). Thus, salivary cortisol has been associated with ASD and anxiety symptoms, but not consistently. Given that both elevated and blunted salivary responses reflect stimulus-bound stress reactivity depending on the nature and duration of the stressor (Laurent, Gilliam, Wright, & Fisher, 2015; Slopen, McLaughlin, & Shonkoff, 2014) , these findings may indicate both short and long-term effects of stress in children with FXS. Collectively, the current study and existing data suggest that the relationship between cortisol and the FXS phenotype is unclear with associations between cortisol and both ASD and anxiety features in some work but not in others.
Results using the revised three-index multivariate composite indicated that the groups differed on a single underlying function, with the FXS group having a lower score than the nonsyndromic ASD group. The SAS most strongly contributed to the group differences with the ADAMS also contributing to a moderate degree and the CBCL contributing the least. Given our follow-up analyses showing no group differences on any of the individual measures, the multivariate composite appears to represent a stronger discriminating factor than the SAS and ADAMS individually when the FXS participants are not Alternatively, evidence from our study suggests that the composite is not simply a reflection of ASD features as the three-group analyses with the FXS group dichotomized into those with and without ASD indicated that the composite did not discriminate across these three groups. Thus, despite the group with FXS without ASD having lower SAS scores than the group with FXS with ASD and lower mean social anxiety scores on the ADAMS than the group with nonsyndromic ASD, the groups were not discriminated when the composite was used. Collectively, our results suggest that anxiety and ASD symptoms are closely related in complex ways in these groups and that the measures employed in this study may lack sufficient discrimination or may differ across groups. This conclusion is supported by work showing a bidirectional relationship between internalizing symptoms and ASD features across childhood in a longitudinal community twin sample (Hallett, Ronald, Rijsdijk, & Happé, 2010) . Specifically, ASD-related social affective impairments and restricted and repetitive behaviors were associated with social anxiety with genetic contributions implied (Hallett, Ronald, Rijsdijk, & Happé, 2012) . Also, social anxiety on the ADAMS has been shown to be more strongly related to the general anxiety scale on the ADAMS for those with FXS than it was for those with nonsyndromic ASD (Thurman et al., 2014) indicating that the expression of dimensions of anxiety may differ across clinical groups.
| Summary
Findings from this study confirm that characterizing anxiety as part of the FXS phenotype is complex with a number of cautions raised regarding measurement. First, an attempt to create a multivariate social anxiety composite comprised of parental rating scales, direct observations and a physiological biomarker revealed that the biomarker, salivary cortisol, was unrelated to the other scales and its inclusion prevented the identification of a clear unifying latent trait across the multiple measures. This suggests that salivary cortisol may be a biomarker indicative of a more generalized disrupted arousal system rather than one that is mechanistically specific to social avoidance. Second, we found that the initial rating of the SAS and the social avoidance scale of the ADAMS were strongly associated with the ADOS-2 severity score across both the FXS and nonsyndromic ASD groups, with these two measures contributing most strongly to the composite. The current results are generally consistent with our earlier findings that initial social avoidance characterized all males with FXS, whereas prolonged social avoidance was associated only with boys with FXS who had elevated ASD features (Roberts et al., 2007) .
As such, we interpret the composite to reflect ASD symptom severity along with elements of social anxiety, recognizing that features of ASD and social anxiety clearly overlap and that measures of these complex traits likely represent elements from both disorders (e.g., social anxiety could drive scores on the ADOS-2 and vice versa).
| Limitations and future directions
Although there are a number of strengths of this study, including our focus on males who are low functioning, implementation of multiple measures including a biomarker in a cross syndrome design, limitations exist. Our sample sizes are small, particularly for the nonsyndromic ASD group. We also were not able to recruit a sample with nonsyndromic ASD that was matched on both nonverbal IQ and expressive language to our sample with FXS despite that being our goal. The primary barrier we encountered was that males with nonsyndromic ASD who met the minimum language requirements nearly universally had a higher nonverbal IQ than those with FXS. Participants with nonsyndromic ASD who had a similar nonverbal IQ were often nonverbal or did not meet the minimum language inclusion criteria highlighting a potential phenotypic distinction across these two groups (Thurman, McDuffie, Hagerman, Josol, & Abbeduto, 2017) . In addition, the instruments were constrained by those available through the larger parent study that this study was drawn from. Future studies should have larger samples, include females, include more targeted instruments (e.g., the Aberrant Behavior Checklist-FXS adaptation; Sansone et al., 2012) and employ a longitudinal design to examine potential developmental effects that are beyond the scope of this study. Also, future work should examine these relationships in younger children to determine if these same relationships are present earlier in development and if precursors for later emerging anxiety symptoms might be present in young children which could direct treatment efforts. Questions regarding the inter-relationship between anxiety and ASD features in FXS clearly need additional study including longitudinal studies that investigate the emergence, trajectory, and co-occurrence of both disorders. Future work that investigates the potential role of the GABA system is needed particularly given its potential as a targeted treatment (Lozano, Hare, & Hagerman, 2014) .
This is particularly salient given recent evidence that social communication difficulties in a population-based sample predicted elevated features of social anxiety while social anxiety did not predict later social communication symptoms (Pickard, Rijsdijk, Happé, & Mandy, 2017) .
